These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 24625776)
1. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Wagle N; Grabiner BC; Van Allen EM; Hodis E; Jacobus S; Supko JG; Stewart M; Choueiri TK; Gandhi L; Cleary JM; Elfiky AA; Taplin ME; Stack EC; Signoretti S; Loda M; Shapiro GI; Sabatini DM; Lander ES; Gabriel SB; Kantoff PW; Garraway LA; Rosenberg JE Cancer Discov; 2014 May; 4(5):546-53. PubMed ID: 24625776 [TBL] [Abstract][Full Text] [Related]
2. [Targeting mTOR and identification of « exceptional responders »]. Robert J Bull Cancer; 2014 Sep; 101(9):775. PubMed ID: 25295532 [No Abstract] [Full Text] [Related]
4. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683 [TBL] [Abstract][Full Text] [Related]
5. Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA. Pan S; Li S; Xiao M; Chen D; Li J Invest New Drugs; 2021 Aug; 39(4):1197-1199. PubMed ID: 33745098 [TBL] [Abstract][Full Text] [Related]
6. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. Goebell PJ; Doehn C; Grüllich C; Grünwald V; Steiner T; Ehneß R; Welslau M Future Oncol; 2017 Jul; 13(17):1463-1471. PubMed ID: 28523933 [TBL] [Abstract][Full Text] [Related]
7. Response and acquired resistance to everolimus in anaplastic thyroid cancer. Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501 [TBL] [Abstract][Full Text] [Related]
8. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899 [TBL] [Abstract][Full Text] [Related]
9. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065 [TBL] [Abstract][Full Text] [Related]
10. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Adib E; Klonowska K; Giannikou K; Do KT; Pruitt-Thompson S; Bhushan K; Milstein MI; Hedglin J; Kargus KE; Sholl LM; Tsuji J; Hyman DM; Sisk A; Shapiro GI; Vargas HA; Harding JJ; Voss MH; Iyer G; Kwiatkowski DJ Clin Cancer Res; 2021 Jul; 27(14):3845-3853. PubMed ID: 33727259 [TBL] [Abstract][Full Text] [Related]
11. Genomic case report of a low grade bladder tumor metastasis to lung. Van Every MJ; Dancik G; Paramesh V; Gurda GT; Meier DR; Cash SE; Richmond CS; Guin S BMC Urol; 2018 Sep; 18(1):74. PubMed ID: 30176882 [TBL] [Abstract][Full Text] [Related]
13. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. Palma N; Morris JC; Ali SM; Ross JS; Pal SK Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722 [No Abstract] [Full Text] [Related]
14. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410 [TBL] [Abstract][Full Text] [Related]
15. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Anand K; Patel T; Niravath P; Rodriguez A; Darcourt J; Belcheva A; Boone T; Ensor J; Chang J Sci Rep; 2021 Jan; 11(1):82. PubMed ID: 33420229 [TBL] [Abstract][Full Text] [Related]
17. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing. Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320 [TBL] [Abstract][Full Text] [Related]
18. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461 [TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. Narayanan S; Lam A; Vaishampayan U; Harshman L; Fan A; Pachynski R; Poushnejad S; Haas D; Li S; Srinivas S Clin Genitourin Cancer; 2016 Oct; 14(5):432-437. PubMed ID: 27068017 [TBL] [Abstract][Full Text] [Related]
20. Genome sequencing identifies a basis for everolimus sensitivity. Iyer G; Hanrahan AJ; Milowsky MI; Al-Ahmadie H; Scott SN; Janakiraman M; Pirun M; Sander C; Socci ND; Ostrovnaya I; Viale A; Heguy A; Peng L; Chan TA; Bochner B; Bajorin DF; Berger MF; Taylor BS; Solit DB Science; 2012 Oct; 338(6104):221. PubMed ID: 22923433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]